325,969 Shares in Burning Rock Biotech Limited (NASDAQ:BNR) Acquired by Crcm LP

Crcm LP purchased a new stake in shares of Burning Rock Biotech Limited (NASDAQ:BNR) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 325,969 shares of the company’s stock, valued at approximately $2,200,000. Burning Rock Biotech comprises 0.9% of Crcm LP’s portfolio, making the stock its 5th largest position. Crcm LP owned about 3.18% of Burning Rock Biotech at the end of the most recent reporting period.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR opened at $4.90 on Tuesday. Burning Rock Biotech Limited has a one year low of $2.62 and a one year high of $8.99. The firm’s 50 day simple moving average is $6.60 and its two-hundred day simple moving average is $5.27. The stock has a market capitalization of $50.20 million, a P/E ratio of -1.63 and a beta of 0.55.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.